Safusidenib

Overview

Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1 . Safusidenib impairs tumor activity in chondrosarcoma. Safusidenib exhibits activity against IDH1R132H , and IDH1R132C with IC 50 s of 15, and 130 nM in assays without any preincubation, respectively.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Isocitrate Dehydrogenase (IDH)

Product Information

• Catalog No.: HY-145594
• CAS No.: 1898206-17-1
• Molecular Formula: C25H18Cl3FN2O4
• Molecular Weight: 535.78
• Purity: 99.05%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.67 mM); Clear solution
• Availability: In-stock

Source

Original product source